Measles virus vaccine live attenuated
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Measles virus vaccine live attenuated
- Accession Number
- DB10315
- Description
Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Live attenuated measles virus (Schwartz strain)
- Measles vaccine (live)
- Measles virus live antigen
- Measles virus live antigen, A
- Measles virus strain enders' attenuated edmonston live (attenuated) antigen
- Measles virus strain enders' attenuated edmonston live antigen
- Measles virus vaccine live
- Measles virus vaccine live attenuated
- Measles Virus Vaccine Live, Enders' attenuated Edmonston strain
- Measles virus vaccine, inactivated
- Measles virus vaccine, live
- Measles virus vaccine, live, attenuated
- Measles virus vaccine,live attenuated
Pharmacology
- Indication
- Not Available
- Associated Conditions
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataMeasles Virus Vacc Live Att Freez Dried Inj Powder, for solution Subcutaneous Iaf Biovac Inc. 1991-12-31 1997-08-20 Canada 
Measles Virus Vaccine Live Atten Dried Powder, for solution Subcutaneous Connaught Laboratories Ltd. 1982-12-31 2000-07-18 Canada Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image M-M-R II Measles virus vaccine live attenuated (1000 TCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50/0.5mL) + Rubella virus vaccine (1000 TCID50/0.5mL) Powder, for solution Subcutaneous Merck Ltd. 1979-12-31 Not applicable Canada M-M-R II Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Merck Sharp & Dohme Corp. 1971-04-21 Not applicable US 
M-M-R II Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous A-S Medication Solutions 1971-04-21 Not applicable US M-M-R II Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Physicians Total Care, Inc. 1996-08-07 2012-06-30 US Measles Virus Vaccine, Live, Attenuated (dried) Measles virus vaccine live attenuated (1000 unit) + Water (0.6 ml) Kit; Liquid; Powder, for solution Subcutaneous Connaught Laboratories Ltd. 1996-12-11 2000-08-02 Canada Priorix Measles virus vaccine live attenuated (103.0 CCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (103.7 CCID50/0.5mL) + Rubella virus vaccine (103.0 CCID50/0.5mL) Kit; Powder, for solution Intramuscular; Subcutaneous Glaxosmithkline Inc 1998-12-04 Not applicable Canada ProQuad Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (20000 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Varicella Zoster Vaccine (Live/attenuated) (9772 [PFU]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Merck Sharp & Dohme Corp. 2015-07-01 Not applicable US ProQuad Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (20000 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Varicella Zoster Vaccine (Live/attenuated) (9772 [PFU]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Merck Sharp & Dohme Limited 2005-09-06 2018-08-31 US ProQuad Measles virus vaccine live attenuated (3 log10 tcid50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (4.3 log10 tcid50/0.5mL) + Rubella virus vaccine (3 log10 tcid50/0.5mL) + Varicella Zoster Vaccine (Live/attenuated) (3.99 log10 tcid50/0.5mL) Powder, for solution Subcutaneous Merck Ltd. 2014-05-09 Not applicable Canada
Categories
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- MFZ8I7277D
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
- AHFS Codes
- 80:12.00 — Vaccines
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention BCG Infection / Immune Response / Reaction - Vaccine 1 4 Completed Prevention Chickenpox / Hepatitis A / Mumps / Rubella / Rubeola 1 4 Completed Prevention Encephalitis, Japanese B / Mumps / Rubella / Rubeola 1 4 Completed Prevention Hepatitis A Virus 1 4 Completed Prevention Mumps / Rubella / Rubeola 2 3 Completed Prevention Acellular Pertussis / Diphtheria / Poliomyelitis / Tetanus 1 3 Completed Prevention Acellular Pertussis / Diphtheria / Tetanus 1 3 Completed Prevention Bacterial Infections / Neisseria Meningitidis / Virus Diseases 2 3 Completed Prevention Bacterial Infections / Virus Diseases 1 3 Completed Prevention Chickenpox Vaccines / Varicella 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for suspension Subcutaneous Injection, powder, for suspension Intramuscular; Subcutaneous 1000 CCID50/0.5mL Injection, powder, lyophilized, for solution Subcutaneous 0.5 ml Powder, for solution Subcutaneous Kit; liquid; powder, for solution Subcutaneous Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous 1000 TCID Injection, powder, for solution Intramuscular; Subcutaneous 103 CCID50/0.5mL Injection, powder, for solution Subcutaneous 103 CCID50/0.5mL Kit; powder, for solution Intramuscular; Subcutaneous Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous 10 CCID Injection, powder, for solution Subcutaneous 10 CCID Injection, powder, lyophilized, for solution Subcutaneous 10 CCID Injection, powder, for suspension Intramuscular; Subcutaneous 1000 [TCID_50]/0.5mL Injection, powder, lyophilized, for suspension Intramuscular; Subcutaneous 1000 [TCID_50]/0.5mL Powder, for solution Subcutaneous Injection, powder, lyophilized, for suspension Intramuscular; Subcutaneous 3 log10/0.5ml Injection Subcutaneous 1000 CCID50/0.5mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on December 01, 2015 13:03 / Updated on October 23, 2020 21:54
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates